References
- Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors 2001. JAMA. 2003; 289: 76-79.
- Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. Clin Med Insights: Cardiol. 2014; 8(S3): 23-33.
- Khalyfa A, Bhushan B, Hegazi M, Kim J, Kheirandish-Gozal L, Bhattacharjee R, et al. Fatty-acid binding protein 4 gene variants and childhood obesity: potential implications for insulin sensitivity and CRP levels. Lipids Health Dis. 2010; 9: 18. http://www.lipidworld.com/content/9/1/18.
- Lee C-H, Lui DTW, Lam KSL. Adipocite Fatty Acid-Binding Protein, Cardiovascular Disease and Mortality. Front Immunol. 2021; 12: Article 589206.
- Xiao Y, Xiao X, Xu A, Chen X, Tang W, Zhou Z. Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes. J Diabetes Complicat. 2018; 32: 1100-1104.
- Tso AWK, Xu A, Sham PC, Wat NMS, Wang Y, Fong CHY, et al. Serum Adipocyte Fatty Acid–Binding Protein as a New Biomarker Predicting the Development of Type 2 Diabetes. A 10-year prospective study in a Chinese cohort. Diabetes Care. 2007; 30 (10): 2667-2672.
- Hardaway AL, Podgorski I. IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem. 2013; 5(10): 1089-1108.
- Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008; 7(6): 489-503.
- Floresta G, Pistarà V, Amata E, Dichiara M, Marrazzo A, Prezzavento O, et al. Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systemic review. Eur J Med Chem. 2017; 138: 854-873.
- Lee MYK, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. Br J Pharmacol. 2011; 162: 1564-1576.
- Lin W, Huang X, Zhang L, Chen D, Wang D, Peng Q, et al. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS ONE. 2012; 7(8): e44570.
- Furuhashi M, Sakuma I, Morimoto T, Higashiura Y, Sakai A, Matsumoto M, et al. Treatment with anagliptin, a DDP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovasc Diabetol. 2020; 19: 89.
- Song J, Ren P, Zhang L, Wang XL, Chen L, Shen YH. Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4. Biochem Biophys Res Commun. 2010; 393: 89-94.
- Mansego ML, Martinez F, Martinez-Larrad MT, Zabena C, Rojo G, Morcillo S, et al. Common Variants of the Liver Fatty Acid Binding Protein Gene Influence the risk of Type 2 Diabetes and Insulin Resistance in Spanish Population. PLoS ONE. 2012; 7(3): e31853.
- Furuhashi M, Mita T, Moniwa N, Hoshina K, Ishimura S, Fuseya T, et al. Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. Hypertens Res. 2015; 38: 252-259.
- Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. PNAS. 2006; 103(18): 6970-2975.
- Mukamal KJ, Wilk JB, Biggs ML, Jensen MK, Ix JH, Kizer JR, et al. Common FABP4 Genetic Variants and Plasma Levels of Fatty Acid Binding Protein 4 in Older Adults. Lipids. 2013; 48(11): 1169-1175.
- Tönjes A, Kralisch S, Lössner U, Kovacs P, Blüher M, Stumvoll M, et al. Metabolic and genetic predictors of circulating adipocyte fatty acid-binding protein. Int J Obes. 2012; 36(6): 766-773.
- Lucena-Aguilar G, Sánchez-López AM, Barberán-Aceituno C, Carrillo-Ávila JA, López-Guerrero JA, Aguilar-Quesada R. DNA Source Selection for Downstream Applications Based on DNA Quality Indicators Analysis. Biopreserv Biobank. 2016; 14(4): 264-270.
- Chan K-H K, Song Y, Hsu Y-H, You N-CY, Tinker LF, Liu S. Common Genetic Variants in Fatty Acid–Binding Protein-4 (FABP4) and Clinical Diabetes Risk in the Women’s Health Initiative Observational study. Obes. 2010; 18(9): 1812–1820.